Online inquiry

IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3319MR)

This product GTTS-WQ3319MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets lukG&lukH gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000791407.1; WP_000791411.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59700810; 59700811
UniProt ID A0A390DBJ6; A0A390DBJ6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3319MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14419MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ7077MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ8700MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ11610MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ3307MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ13125MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ3208MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ5860MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW